Skip to content
1887

Journal of General Virology header logo Journal of General Virology

Volume 97, Issue 4

Myristoylation increases the CD8T-cell response to a GFP prototype antigen delivered by modified vaccinia virus Ankara No Access

Abstract

Activation of CD8T-cells is an essential part of immune responses elicited by recombinant modified vaccinia virus Ankara (MVA). Strategies to enhance T-cell responses to antigens may be particularly necessary for broadly protective immunization against influenza A virus infections or for candidate vaccines targeting chronic infections and cancer. Here, we tested recombinant MVAs that targeted a model antigen, GFP, to different localizations in infected cells. characterization demonstrated that GFP accumulated in the nucleus (MVA-nls–GFP), associated with cellular membranes (MVA-myr–GFP) or was equally distributed throughout the cell (MVA–GFP). On vaccination, we found significantly higher levels of GFP-specific CD8T-cells in MVA-myr–GFP-vaccinated BALB/c mice than in those immunized with MVA–GFP or MVA-nls–GFP. Thus, myristoyl modification may be a useful strategy to enhance CD8T-cell responses to MVA-delivered target antigens.

  • Received:
  • Accepted:
  • Published Online:
© 2016 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000425
2016-04-01
2025-04-22
Loading full text...

Full text loading...

References

  1. Ahlers J. D., Belyakov I. M. 2010; Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 115:1678–1689 [View Article][PubMed]
     [Google Scholar]
  2. Altenburg A. F., Kreijtz J. H., de Vries R. D., Song F., Fux R., Rimmelzwaan G. F., Sutter G., Volz A. 2014; Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6:2735–2761 [View Article][PubMed]
     [Google Scholar]
  3. Becker P. D., Nörder M., Weissmann S., Ljapoci R., Erfle V., Drexler I., Guzmán C. A. 2014; Gene expression driven by a strong viral promoter in MVA increases vaccination efficiency by enhancing antibody responses and unmasking CD8+T cell epitopes. Vaccines (Basel) 2:581–600 [View Article][PubMed]
     [Google Scholar]
  4. Boulanger D., Green P., Jones B., Henriquet G., Hunt L. G., Laidlaw S. M., Monaghan P., Skinner M. A. 2002; Identification and characterization of three immunodominant structural proteins of fowlpox virus. J Virol 76:9844–9855 [View Article][PubMed]
     [Google Scholar]
  5. Brandler S., Lepelley A., Desdouits M., Guivel-Benhassine F., Ceccaldi P. E., Lévy Y., Schwartz O., Moris A. 2010; Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect. J Virol 84:5314–5328 [View Article][PubMed]
     [Google Scholar]
  6. Bronte V., Carroll M. W., Goletz T. J., Wang M., Overwijk W. W., Marincola F., Rosenberg S. A., Moss B., Restifo N. P. 1997; Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A 94:3183–3188 [View Article][PubMed]
     [Google Scholar]
  7. Brown L. E., Kelso A. 2009; Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol 87:300–308 [View Article][PubMed]
     [Google Scholar]
  8. Broyles S. S., Li J., Moss B. 1991; Promoter DNA contacts made by the vaccinia virus early transcription factor. J Biol Chem 266:15539–15544[PubMed]
     [Google Scholar]
  9. Chan T. O., Zhang J., Rodeck U., Pascal J. M., Armen R. S., Spring M., Dumitru C. D., Myers V., Li X., other authors. 2011; Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity. Proc Natl Acad Sci U S A 108:E1120–E1127 [View Article][PubMed]
     [Google Scholar]
  10. Gasteiger G., Kastenmuller W., Ljapoci R., Sutter G., Drexler I. 2007; Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol 81:11925–11936 [View Article][PubMed]
     [Google Scholar]
  11. Gilbert S. C. 2013; Clinical development of modified vaccinia virus Ankara vaccines. Vaccine 31:4241–4246 [View Article][PubMed]
     [Google Scholar]
  12. Goebel S. J., Johnson G. P., Perkus M. E., Davis S. W., Winslow J. P., Paoletti E. 1990; The complete DNA sequence of vaccinia virus. Virology 179: 247266 517–563 [CrossRef]
     [Google Scholar]
  13. Gómez C. E., Perdiguero B., García-Arriaza J., Esteban M. 2013; Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines 12:1395–1416 [View Article][PubMed]
     [Google Scholar]
  14. Kastenmuller W., Drexler I., Ludwig H., Erfle V., Peschel C., Bernhard H., Sutter G. 2006; Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology 350:276–288 [View Article][PubMed]
     [Google Scholar]
  15. Kastenmuller W., Gasteiger G., Gronau J. H., Baier R., Ljapoci R., Busch D. H., Drexler I. 2007; Cross-competition of CD8+T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med 204:2187–2198 [View Article][PubMed]
     [Google Scholar]
  16. Katsafanas G. C., Moss B. 2007; Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions. Cell Host Microbe 2:221–228 [View Article][PubMed]
     [Google Scholar]
  17. Kreijtz J. H., Gilbert S. C., Sutter G. 2013; Poxvirus vectors. Vaccine 31:4217–4219 [View Article][PubMed]
     [Google Scholar]
  18. Kreijtz J. H., Goeijenbier M., Moesker F. M., van den Dries L., Goeijenbier S., De Gruyter H. L., Lehmann M. H., Mutsert G., van de Vijver D. A., other authors. 2014; Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis 14:1196–1207 [View Article][PubMed]
     [Google Scholar]
  19. Kremer M., Suezer Y., Volz A., Frenz T., Majzoub M., Hanschmann K. M., Lehmann M. H., Kalinke U., Sutter G. 2012a; Critical role of perforin-dependent CD8+T cell immunity for rapid protective vaccination in a murine model for human smallpox. PLoS Pathog 8:e1002557 [View Article][PubMed]
     [Google Scholar]
  20. Kremer M., Volz A., Kreijtz J. H., Fux R., Lehmann M. H., Sutter G. 2012b; Easy and efficient protocols for working with recombinant vaccinia virus MVA. Methods Mol Biol 890:59–92 [View Article][PubMed]
     [Google Scholar]
  21. Mackett M., Smith G. L., Moss B. 1982; Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 79:7415–7419 [View Article][PubMed]
     [Google Scholar]
  22. Maurer-Stroh S., Eisenhaber B., Eisenhaber F. 2002; N-terminal N-myristoylation of proteins: refinement of the sequence motif and its taxon-specific differences. J Mol Biol 317:523–540 [View Article][PubMed]
     [Google Scholar]
  23. Nörder M., Becker P. D., Drexler I., Link C., Erfle V., Guzmán C. A. 2010; Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model. PLoS One 5:e11400 [View Article][PubMed]
     [Google Scholar]
  24. Pascutti M. F., Rodríguez A. M., Falivene J., Giavedoni L., Drexler I., Gherardi M. M. 2011; Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells. J Virol 85:5532–5545 [View Article][PubMed]
     [Google Scholar]
  25. Sebastian S., Gilbert S. C. 2016; Recombinant modified vaccinia virus Ankara-based malaria vaccines. Expert Rev Vaccines 15:91–103 [View Article][PubMed]
     [Google Scholar]
  26. Sutter G., Moss B. 1992; Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 89:10847–10851 [View Article][PubMed]
     [Google Scholar]
  27. Sutter G., Wyatt L. S., Foley P. L., Bennink J. R., Moss B. 1994; A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12:1032–1040 [View Article][PubMed]
     [Google Scholar]
  28. Tscharke D. C., Woo W.-P., Sakala I. G., Sidney J., Sette A., Moss D. J., Bennink J. R., Karupiah G., Yewdell J. W. 2006; Poxvirus CD8+T-cell determinants and cross-reactivity in BALB/c mice. J Virol 80:6318–6323 [View Article][PubMed]
     [Google Scholar]
  29. Volz A., Sutter G. 2013; Protective efficacy of modified vaccinia virus Ankara in preclinical studies. Vaccine 31:4235–4240 [View Article][PubMed]
     [Google Scholar]
  30. Wang P., Palese P., O'Neill R. E. 1997; The NPI-1/NPI-3 (karyopherin α) binding site on the influenza A virus nucleoprotein NP is a nonconventional nuclear localization signal. J Virol 71:1850–1856[PubMed]
     [Google Scholar]
  31. Yang Z., Cao S., Martens C. A., Porcella S. F., Xie Z., Ma M., Shen B., Moss B. 2015; Deciphering poxvirus gene expression by RNA sequencing and ribosome profiling. J Virol 89:6874–6886 [View Article][PubMed]
     [Google Scholar]
/content/journal/jgv/10.1099/jgv.0.000425
Loading
Myristoylation increases the CD8+T-cell response to a GFP prototype antigen delivered by modified vaccinia virus Ankara
J. Gen. Virol. 97, 934 (2016); https://doi.org/10.1099/jgv.0.000425
/content/journal/jgv/10.1099/jgv.0.000425
/content/journal/jgv/10.1099/jgv.0.000425
Loading

Data & Media loading...

Supplements

Supplementary Data

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error